Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and effects of vedolizumab given as a subcutaneous injection in children and teenagers aged 2 to 17 years who have moderate to severe active ulcerative colitis or Crohns disease. The study aims to understand any medical problems related to the treatment, the time until hospital visits due to bowel inflammation are needed, and the impact on quality of life. This is a phase 3b extension study involving participants from a previous trial who responded well or did not respond to vedolizumab treatment. Participants who responded well in the previous study will continue to receive vedolizumab subcutaneously either via a prefilled syringe with an autoinjector pen or with a needle safety device. Dosage depends on weight, with injections given every two or four weeks for up to 120 weeks or until the treatment becomes commercially available or the study ends. Those who did not respond well or recently used corticosteroids will not receive the drug but will be followed for approximately two years as an observational group. Throughout the study, participants will visit their clinic multiple times for safety monitoring and assessments. Researchers will track adverse events and serious side effects up to 18 weeks after the last dose, as well as other safety events in the observational group. They will also measure the time to major inflammatory bowel disease events and changes in quality of life using questionnaires. The total participation time can be up to two years from the first dose.
Actively Recruiting
Researchers are evaluating the drug sarilumab in children and adolescents aged 1 to 17 years with Systemic Juvenile Idiopathic Arthritis sJIA. The study aims to describe how sarilumab behaves in the body pharmacokinetics, its effects pharmacodynamics, efficacy, and long-term safety in this population to determine an appropriate dose and treatment regimen. This is a Phase 2 open-label trial sponsored by Sanofi. Participants will receive one of two ascending doses or an additional intermediate dose of sarilumab by subcutaneous injection based on body weight. The selected dose will be administered once identified. Treatment begins with a 12-week core phase followed by a 144-week extension phase during which sarilumab continues to be given. After treatment, there is a 6-week post-treatment follow-up. Throughout the 166-week total study duration, participants will be monitored with various assessments including blood tests to measure drug levels and disease activity, evaluations of adverse events, and questionnaires to assess well-being and symptoms. Measurements like juvenile arthritis response rates and disease activity scores are tracked during both the core and extension phases. Safety, including injection site reactions and changes in glucocorticoid use, is also followed closely.
Actively Recruiting
Researchers are evaluating whether tralokinumab given as subcutaneous injections along with topical corticosteroids TCS is safe and effective for treating moderate-to-severe atopic dermatitis AD in children and infants. The trial involves two age groups children aged 2 to under 12 years and infants aged 6 months to under 2 years. Children are randomized to receive either tralokinumab plus TCS or placebo plus TCS, while infants receive open-label tralokinumab plus TCS. This Phase 3 trial will last up to four years with visits every two weeks during the first year and every six weeks thereafter, including some phone visits.
Actively Recruiting
Researchers are evaluating the safety and performance of Abbotts commercially available Structural Heart SH devices in real-world hospital settings. This observational registry collects data to meet regulatory requirements, such as the European Union Medical Device Regulations 2017745, by actively monitoring these devices after market approval. The study includes patients undergoing standard care procedures involving Abbott SH devices, with a focus on confirming device safety and performance across multiple device types. Participants receive one or more Abbott SH devices during routine hospital procedures, including Amplatzer Occlusion Devices for septal defects and Epic Surgical Tissue Heart Valve devices for heart valve replacement. The registry enrolls patients either before the procedure or shortly after, depending on the device type, with follow-up visits aligned with standard care schedules. Follow-up may include discharge or 7-day post-procedure visits, short-term 1-3 months, mid-term 6 months, and long-term up to 12 months or even 10 years assessments depending on the device used. A specific surgical valve sub-study collects additional data for certain valve sizes to support regulatory approval in the US. Participants are monitored through their routine care visits, which may occur in person, by phone, or virtually. Data collected include safety and effectiveness outcomes at various time points post-procedure. The registry plans to enroll approximately 500 subjects annually across about 25 global sites, with follow-up duration varying by device type to cover short- and long-term safety and performance. The total study completion is expected by November 2039, allowing extended monitoring of patient outcomes.
Actively Recruiting
Researchers are evaluating new treatment strategies for children and adults with newly diagnosed and relapsed rhabdomyosarcoma RMS in a multi-arm, multi-stage clinical trial called FaR-RMS. The study aims to assess the impact of new drug regimens, the effects of changing maintenance therapy duration, the influence of radiotherapy dose and timing, and the use of genetic and imaging markers to improve risk stratification and predict outcomes. Participants may receive various chemotherapy drugs including irinotecan, ifosfamide, vincristine, actinomycin, doxorubicin, vinorelbine, cyclophosphamide, temozolomide, and regorafenib administered through infusions or oral tablets on specific schedules. Radiotherapy is also given in different doses and timings depending on the treatment arm. The study includes dose-finding phases and multiple randomizations based on patient risk group and disease status. Throughout the study, participants undergo regular assessments including monitoring for event-free survival, local failure-free survival, toxicity, response to treatment, and quality of life using questionnaires. Follow-up may continue for several years to track progression and survival. Safety is closely monitored with evaluations of acute and late complications, and treatment tolerability is assessed. The study involves written consent and requires participants to use contraception if applicable during and after treatment.